Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16543622 | 1.00 | TSHR (0.39) | TSHRLMNAKDM4EHSD17B10MGAM | |
| SCHEMBL12092171 | 1.00 | TSHR (0.39) | TSHRLMNAKDM4EHSD17B10MGAM | |
| SCHEMBL9526687 | 1.00 | TSHR (0.39) | TSHRLMNAKDM4EHSD17B10MGAM | |
| Hydrochloric Acid SCHEMBL19617019 | 0.98 | LMNA (0.41) | TSHRLMNAKDM4EHSD17B10MGAM | |
| SCHEMBL3149738 | 0.96 | — | — | |
| SCHEMBL7648165 | 0.89 | TSHR (0.48) | TSHRLMNAKDM4EHSD17B10MGAM | |
| Trifluoroacetic Acid SCHEMBL29639406 | 0.88 | CES2 (0.34) | TSHRLMNAKDM4E | |
| SCHEMBL26199209 | 0.86 | MEN1 (0.39) | TSHRKDM4EMEN1KMT2A | |
| SCHEMBL6463788 | 0.86 | TSHR (0.50) | TSHRLMNAKDM4EHSD17B10MGAM | |
| Hydrochloric Acid SCHEMBL25174368 | 0.85 | KDM4E (0.33) | LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233676-A1 | COMPOSITIONS AND METHODS RELATED TO A COMBINATION THERAPY OF STING AGONISTS AND IMMUNE CHECKPOINT INHIBITORS | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025233679-A1 | COMPOSITIONS AND METHODS RELATED TO A COMBINATION THERAPY OF STING AGONISTS AND ANTIBODY DRUG CONJUGATES | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | disclosed |
| EP-4615852-A1 | STING AGONISTS | LigaChem Biosciences Inc. (KR) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024100449-A1 | STING AGONISTS | LEGOCHEM BIOSCIENCES, INC. (KR) | 2024-05-16 | — | — | WO | disclosed |
| US-20220062258-A1 | Heterocyclic derivatives | MERCK PATENT GMBH (DE) | 2022-03-03 | — | — | US | disclosed |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-09 | — | — | US | disclosed |
| WO-2020152067-A1 | HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-07-30 | — | — | WO | disclosed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | DAO, LPO, TYRO3 | TSHR 806/4885LMNA 4642/4885KDM4E 1234/4885 |
| US-20220062258-A1 | Heterocyclic derivatives | XIAP, UBQLN1, UBQLN2 | TSHR 4395/4885LMNA 847/4885KDM4E 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.